Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morphine for Resting Breathlessness in Severe Illness and Palliative Care (MORE-B)
2026-525838-32-00Phase 4Authorised
- Sponsor
- Region Skåne
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in chronic condition and airway morbidity comparing Morphine with Placebo (sodium chloride) (2 arms). Primary endpoint: Change in self-rated breathlessness at 60 minutes. Planned start Jun 2026; status: authorised.
02
Drugs
morphine
03
Conditions
chronic conditionairway morbidity
Beyond the preview
Go deeper on 2026-525838-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525838-32-00.